Figures & data
Figure 1 Cell-penetrating peptide T9(dR) or TP condensed siRNA and formed nanoparticles with siRNA. (A) Gel retardation assay and (B) size of nanoparticles at 25°C and 37°C. **P-values <0.05 were considered to be significant.
![Figure 1 Cell-penetrating peptide T9(dR) or TP condensed siRNA and formed nanoparticles with siRNA. (A) Gel retardation assay and (B) size of nanoparticles at 25°C and 37°C. **P-values <0.05 were considered to be significant.](/cms/asset/3570cba6-9aee-4642-84b7-77b2ba7d403d/dddt_a_12182053_f0001_b.jpg)
Figure 2 Cell viability treated with complex of T9(dR) or TP and tested by MTT assay. (A) T9(dR) and (B) TP.
![Figure 2 Cell viability treated with complex of T9(dR) or TP and tested by MTT assay. (A) T9(dR) and (B) TP.](/cms/asset/75e9fa1e-2cc5-438a-acc6-2695be50baf0/dddt_a_12182053_f0002_b.jpg)
Figure 3 T9(dR) or TP transported siRNA into (A) 293T and (B) A549 cell lines. After T9(dR) or TP and cy3-conjugated siGFP were incubated for 15 minutes, the complex was transfected into cells seeded in eight-well chamber. At 24 hours post-transfection, cells were fixed, mounted with DAPI, and observed under a microscope (20×).
![Figure 3 T9(dR) or TP transported siRNA into (A) 293T and (B) A549 cell lines. After T9(dR) or TP and cy3-conjugated siGFP were incubated for 15 minutes, the complex was transfected into cells seeded in eight-well chamber. At 24 hours post-transfection, cells were fixed, mounted with DAPI, and observed under a microscope (20×).](/cms/asset/42d86ff0-7758-41ea-a184-f4db7dd08769/dddt_a_12182053_f0003_c.jpg)
Figure 4 The delivery efficiency of T9(dR) with siRNA in A549, 293T, RAW, and MDCK cells (A–D). After T9(dR) and cy3-conjugated siGFP were incubated for 15 minutes, the complex was transfected into cells seeded in six-well plate. At 24 hours post-transfection, cells were run in a flow cytometer to detect cy3-positive cells. **P-values <0.05 were considered to be significant.
![Figure 4 The delivery efficiency of T9(dR) with siRNA in A549, 293T, RAW, and MDCK cells (A–D). After T9(dR) and cy3-conjugated siGFP were incubated for 15 minutes, the complex was transfected into cells seeded in six-well plate. At 24 hours post-transfection, cells were run in a flow cytometer to detect cy3-positive cells. **P-values <0.05 were considered to be significant.](/cms/asset/925a21f6-1e8a-40f9-8ebd-f9e21b3ed8cd/dddt_a_12182053_f0004_b.jpg)
Figure 5 T9(dR) delivered functional siRNA into (A) MDCK and (B) A549 cell lines. MDCK and A549 cells were treated with siNP and infected with influenza virus of MOI =0.01. At 24 hours post-infection, viral titers in supernatant were titrated by standard plaque assay. **P-values <0.05 were considered to be significant.
![Figure 5 T9(dR) delivered functional siRNA into (A) MDCK and (B) A549 cell lines. MDCK and A549 cells were treated with siNP and infected with influenza virus of MOI =0.01. At 24 hours post-infection, viral titers in supernatant were titrated by standard plaque assay. **P-values <0.05 were considered to be significant.](/cms/asset/50351528-21ef-4189-99b1-1d44ef4d06bf/dddt_a_12182053_f0005_b.jpg)
Figure 6 siNP transported by T9(dR) inhibited the replication of PR8 influenza virus in vivo. BALB/c mice were divided into seven groups, intravenously injected PBS, siGFP, siNP with T9(dR) or TP, and infected with influenza. Mouse weight was recorded (A) and survival was calculated (B). **P-values <0.05 were considered to be significant.
![Figure 6 siNP transported by T9(dR) inhibited the replication of PR8 influenza virus in vivo. BALB/c mice were divided into seven groups, intravenously injected PBS, siGFP, siNP with T9(dR) or TP, and infected with influenza. Mouse weight was recorded (A) and survival was calculated (B). **P-values <0.05 were considered to be significant.](/cms/asset/9c714b15-14a7-4a09-8fa2-ffd0196af5a9/dddt_a_12182053_f0006_b.jpg)